Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
30.6M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
3M
-
Shares change
-
+1.81M
-
Total reported value, excl. options
-
$15.7M
-
Value change
-
+$10.1M
-
Put/Call ratio
-
0.27
-
Number of buys
-
23
-
Number of sells
-
-16
-
Price
-
$5.24
Significant Holders of Vistagen Therapeutics, Inc. - Common Stock (VTGN) as of Q3 2023
47 filings reported holding VTGN - Vistagen Therapeutics, Inc. - Common Stock as of Q3 2023.
Vistagen Therapeutics, Inc. - Common Stock (VTGN) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3M shares
of 30.6M outstanding shares and own 9.81% of the company stock.
Largest 10 shareholders include COMMODORE CAPITAL LP (1.58M shares), VANGUARD GROUP INC (254K shares), Ikarian Capital, LLC (229K shares), Schonfeld Strategic Advisors LLC (139K shares), SPHERA FUNDS MANAGEMENT LTD. (100K shares), BML Capital Management, LLC (100K shares), BlackRock Inc. (88K shares), BLAIR WILLIAM & CO/IL (85.2K shares), GROUP ONE TRADING, L.P. (75.3K shares), and GEODE CAPITAL MANAGEMENT, LLC (73.2K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.